Pet Screening. A new screening test For dogs at risk. One in four dogs will get cancer at some time in their lives. Lymphoma, also called lymphosarcoma, which is abbreviated as LSA, is one of the most common cancers in dogs, accounting for about 20% of all canine malignant forms of cancer. It is a disease of the lymph nodes and lymphocytes and can be found throughout the dog’s body.
Lymphoma is most common in dogs from middle age onwards, although it can develop at any age. Males and females are affected to the same extent, but certain breeds are more prone than others. Predisposed breeds include Golden Retrievers, Boxers, and Westies. There is a strong familial, or congenital, link for lymphoma.
In most cases, a dog with lymphoma will show very few signs. In addition, because lymphoma is a diverse disease, there are wide ranges of symptoms, which can make initial diagnosis difficult. The most common presentation is the appearance of swollen lymph nodes. If left untreated, lymphoma patients will usually succumb to the disease within about 4 weeks from diagnosis. However, lymphoma is very responsive to treatment with modern chemotherapy. Once diagnosed, lymphoma can be very responsive to treatment, and 80% of dogs with the disease may go into remission.
This author has worked with many dogs diagnosed with Lymphoma cancer and reports that with natural supplements, and an anti-cancer diet, her patients have enjoyed quality life for an average of 2 years post diagnosis. She has used this regime successfully for cases with and without chemotherapy for lymphoma.
In many lymphoma cases that present with enlarged peripheral lymph nodes, a biopsy or aspirate of the suspect node can be taken. However, with the more generalised symptoms associated with internal lymph node involvement, other procedures will also be necessary. Complete blood count, blood chemistries, a urinalysis and x-rays, or an ultrasound may be necessary for diagnosis.
A new blood test from Pet Screening has been developed that can detect lymphoma from 1milliliter of a dog’s blood. The test employs the latest “multiple biomarker” technology developed for human cancer detection. This technology provides a greater level of accuracy than previous single marker cancer tests, such as the PSA test for prostate cancer in men. Compared to other diagnostics, the Pet Screen blood test is low cost, minimally invasive and does not require sedation of the pet. If the test results are positive, the veterinarian will be well placed to begin a series of additional tests to determine the extent of the disease and to plan the course of treatment. Time is the key in all successful cancer treatments.
For more information, talk to your family veterinarian, or go to www.pet-screen.com.